| Stocks closed in the green on Monday after a lower open and a back-and-forth trading session. The S&P 500 added 0.7%, and the Nasdaq climbed 0.8%. The Dow gained 0.6%, and the small-cap Russell 2K closed 0.8% higher. Today, futures are slipping in early morning trading. Dow and S&P 500 contracts are currently down 0.3%. This Lithium Stock Could See Massive Growth Γ°ΒΒΒ
An undiscovered lithium stock trading below $0.30 per share just uncovered 8 high-quality targets on unexplored ground.
Drills are turning on later this year, but very few investors know about it yet, so this ground-floor opportunity below $0.30 won't be around much longer. It's a new breed of lithium stock, and shares could be on course to explode. Get the Name and Trading Symbol Here 10-Year US Treasury bond yields are at their highest levels since 2011. Currently, yields are listed at 3.542% on a 10-year bond. The Federal Reserve is expected to announce this month's policy decision during tomorrow's trading session. Markets expect a 0.75% increase. Wynn Resorts [WYNN] - Last Close: $65.89 Casino stocks are moving higher this morning, and Wynn is leading the push. Wynn and other major casino operators are trending this morning, just a day after President Biden announced the pandemic was over. The statement drew some criticism from health experts, but many were relieved to hear the words come from the president. Investors seem to have rediscovered casino stocks in the wake of the news. The sector has struggled, but the long-term downtrend may finally bottom out on this news. WYNN is leading the S&P 500 with a 3.8% gain. My Take: If you're bullish on casino stocks, WYNN could be a good play. It's currently trading near all-time lows and showing strong support at $50. There could also be significant upside if it breaks out of its trading range. BYND Cannasoft [BCAN] - Last Close: $5.50 BYND Cannasoft is rallying for the second day in a row. Yesterday, the company announced it signed an agreement to acquire 100% of Zigi Carmel Initiatives & investments in exchange for $28 million worth of its common stock. The news powered BCAN to a 31.9% gain on Monday, and it carried its momentum through the closing bell and into today's premarket. BCAN is one of today's top performers for a second day in a row as a result of this headline. Shares are up 41.3% on active trading volume. My Take: Be very careful here. You're late in the game if you're planning on getting in now. I wouldn't be surprised if we saw this stock pull back dramatically before the end of the week. Stick and move. Virax Biolabs Group [VRAX] - Last Close: $2.47 A new product launch is boosting shares of Virax Bio. This morning, the biotech company announced the launch and distribution of its Monkeypox Antigen Rapid Test Kit in the European Union and other markets. The test kits are available through the company, and they are designed for use in point-of-care settings such as clinics. They produce results in about 15 minutes. Virax says it's also developing a proprietary T-Cell Test technology to assess an individual's immune risk profile against major global viral threats. VRAX is one of this morning's most active stocks, and it's showing a 17.0% gain. My Take: VRAX has some promising things going on, but I wouldn't go all-in based on this one report. The chart looks pretty ugly, and this stock just debuted last month. If you get in, it might be some time before you see gains. Renovacor [RCOR] - Last Close: $1.90 Renovacor is soaring on buyout news. The micro-cap biotech stock is breaking out after Rocket Pharmaceuticals agreed to acquire the company in an all-stock deal worth roughly $53 million. Under the terms of the deal, RCOR shareholders would receive about $2.60 worth of RCKT stock in exchange for their shares. Rocket said the deal strengthens its position in adeno-associated virus-based gene therapy for cardiac disease and expands its short-term clinical assets for heart condition treatments. Renovacor stockholders are expected to own a 4.6% stake in Rocket after closing, which is expected to occur in Q1 2023 pending shareholder approval and customary closing conditions. RCOR is one of today's top stocks with a 21.1% gain. My Take: There's not much room between RCOR's current price and the proposed acquisition price, so I would steer clear of this one, especially considering its a stock-swap deal. Unless you want to end up with shares of RCKT, I would stay away. |
